Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Common Equity (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Common Equity for 6 consecutive years, with $567.1 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 27.09% to $567.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $567.1 million through Dec 2025, down 27.09% year-over-year, with the annual reading at $567.1 million for FY2025, 27.09% down from the prior year.
  • Common Equity for Q4 2025 was $567.1 million at Relay Therapeutics, down from $607.7 million in the prior quarter.
  • The five-year high for Common Equity was $999.8 million in Q3 2022, with the low at $567.1 million in Q4 2025.
  • Average Common Equity over 5 years is $761.1 million, with a median of $764.9 million recorded in 2023.
  • The sharpest move saw Common Equity skyrocketed 462.14% in 2021, then decreased 27.56% in 2025.
  • Over 5 years, Common Equity stood at $897.8 million in 2021, then grew by 5.84% to $950.2 million in 2022, then decreased by 20.86% to $752.0 million in 2023, then increased by 3.43% to $777.8 million in 2024, then fell by 27.09% to $567.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $567.1 million, $607.7 million, and $665.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.